Results 11 to 20 of about 256,246 (307)

Important questions in drug allergy and hypersensitivity: consensus papers from the 2018 AAAAI/WAO international drug allergy symposium

open access: yesWorld Allergy Organization Journal, 2018
This article is one of a series of international consensus documents developed from the International Drug Allergy Symposium held at the Joint Congress of the American Academy of Allergy, Asthma & Immunology/World Allergy Organization on March 1, 2018 ...
Pascal Demoly, Mariana Castells
doaj   +1 more source

Simulation-based education to improve management of refractory anaphylaxis in an allergy clinic

open access: yesAllergy, Asthma & Clinical Immunology, 2023
Background High-fidelity simulations based on real-life clinical scenarios have frequently been used to improve patient care, knowledge and teamwork in the acute care setting.
Ana M. Copaescu   +10 more
doaj   +1 more source

Automated benchmarking of peptide-MHC class I binding predictions [PDF]

open access: yes, 2015
Motivation: Numerous in silico methods predicting peptide binding to major histocompatibility complex (MHC) class I molecules have been developed over the last decades. However, the multitude of available prediction tools makes it non-trivial for the end-
Greenbaum, Jason   +8 more
core   +3 more sources

Prediction and prevention of allergy and asthma in EAACI journals (2016)

open access: yesClinical and Translational Allergy, 2017
The European Academy of Allergy and Clinical Immunology (EAACI) owns three journals: Allergy, Pediatric Allergy and Immunology and Clinical and Translational Allergy.
Jean Bousquet   +8 more
doaj   +1 more source

The Immunology of Food Allergy [PDF]

open access: yesThe Journal of Immunology, 2014
Abstract Food allergies represent an increasingly prevalent human health problem, and therapeutic options remain limited, with avoidance being mainstay, despite its adverse effects on quality of life. A better understanding of the key immunological mechanisms involved in such responses likely will be vital for development of new ...
Laura K, Johnston   +2 more
openaire   +2 more sources

Welcome to Clinical and Translational Allergy [PDF]

open access: yes, 2011
It is with the greatest satisfaction and pride that the European Academy of Allergy and Clinical Immunology (EAACI) today can launch its first open access scientific journal, "Clinical and Translational Allergy" (CTA). Over many years, EAACI have focused
Jan Lötvall, Victoria Cardona
core   +1 more source

The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference [PDF]

open access: yes, 2016
HLA class I-binding predictions are widely used to identify candidate peptide targets of human CD8+ T cell responses. Many such approaches focus exclusively on a limited range of peptide lengths, typically 9 aa and sometimes 9-10 aa, despite multiple ...
Bardet, Wilfried   +9 more
core   +1 more source

C1 inhibitor deficiency: 2014 United Kingdom consensus document [PDF]

open access: yes, 2015
C1 inhibitor deficiency is a rare disorder manifesting with recurrent attacks of disabling and potentially life-threatening angioedema. Here we present an updated 2014 United Kingdom consensus document for the management of C1 inhibitor-deficient ...
Ashworth, F   +11 more
core   +3 more sources

Highlights and recent developments in skin allergy and related diseases in EAACI journals (2018)

open access: yesClinical and Translational Allergy, 2019
The European Academy of Allergy and Clinical Immunology (EAACI) supports three journals: Allergy, Paediatric Allergy and Immunology as well as Clinical and Translational Allergy.
C. A. Akdis   +6 more
doaj   +1 more source

Conducting retrospective impact analysis to inform a medical research charity’s funding strategies: The case of Asthma UK [PDF]

open access: yes, 2013
© 2013 Hanney et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and ...
Amanda Watt   +44 more
core   +1 more source

Home - About - Disclaimer - Privacy